---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-072685"
form_type: "8-K"
ticker: "HURA"
cik: "0001498382"
company_name: "TuHURA Biosciences, Inc./NV"
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:53:27.774946+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# TuHURA Q1 expenses rise; Phase 3 MCC trial and Kineta merger on track for Q2 2025

## Summary
- Q1 2025 R&D expenses $4.6M (up 28% YoY); G&A $2.4M (up 140% YoY); shares outstanding ~43.7M.
- Initiated Phase 1b/2a trial of IFx-Hu2.0 plus pembrolizumab in first-line Merkel cell carcinoma of unknown primary in May 2025.
- Targeting Q2 2025 close of Kineta acquisition; Phase 2 trial of VISTA mAb in NPM1-mutated AML expected Q3 2025.
- Phase 3 accelerated approval trial of IFx-Hu2.0 in advanced Merkel cell carcinoma expected to start Q2 2025 after lifting partial clinical hold.
- Appointed Dr. Bertrand Le Bourdonnec as EVP Head of Drug Discovery in April 2025; Dr. Craig Tendler joined Board in March 2025.

## SEC filing metadata
- accession: 0000950170-25-072685
- form_type: 8-K
- ticker: HURA
- cik: 0001498382
- company_name: TuHURA Biosciences, Inc./NV
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/0000950170-25-072685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1498382/000095017025072685/hura-20250515.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-072685
- JSON: https://secwatch.observer/filing/0000950170-25-072685.json
- Plain text: https://secwatch.observer/filing/0000950170-25-072685.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.